Orpyx needed to demonstrate the cost-effectiveness of their technology in preventing diabetic foot ulcers (DFU). Gaining a healthcare payer perspective was crucial to developing favorable coverage of the client’s technology, as the client had very little data, and all existing models were predictive – designed specifically to help the client understand their potential value. Over the span of 3 years, TTi collaborated with the client to develop the preliminary C-E model, to identify the data elements needed in future clinical studies, and to update the model as these results became available. From very early on in their product development lifecycle, Orpyx was able to utilize the model developed by TTi to inform their clinical study strategy as well as their product pricing strategy. The model was used repeatedly to update the emerging value proposition of SurroSense Rx in preventing DFU.